Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad671 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Zubeyir Hasan Gun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Scoliosis, Fibrous Dysplasia of Bone, Fibrous Dysplasia, Polyostotic, Hypophosphatemia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CLC NIH HHS, Intramural Research Programs, NIH.
Abstract (Originalsprache)
Context
Fibrous dysplasia (FD) results in fractures, pain, and deformities. Abnormal osteoprogenitor cells overproduce FGF23, leading to hyperphosphaturia in most patients and frank hypophosphatemia in a subset. Studies suggest hypophosphatemia is associated with increased FD-related morbidity. However, the relationship between phosphorus and skeletal complications has not been investigated, and the optimal therapeutic target has not been determined.
Objective
Characterize the impact of serum phosphorus on FD-related morbidity and identify levels associated with increased skeletal complications.
Methods
Natural history study with 240 subjects at a clinical research center who had ≥1 fasting phosphorus level, determined as age- and sex-adjusted Z-scores. Subjects were categorized based on frank hypophosphatemia (Z-score ≤ −2; n = 48); low-normophosphatemia (> −2 to ≤ −1; n = 66); and high-normophosphatemia (> −1 to ≤ 2; n = 125). Main outcomes were fractures, orthopedic surgeries, and scoliosis.
Results
Subjects with frank and low-normophosphatemia had increased fracture and surgery rates vs high-normophosphatemia. The prevalence of moderate to severe scoliosis was similarly higher in the frank and low-normophosphatemia groups. In a subanalysis of patients matched for Skeletal Burden Score ≥35, fracture and surgery rates remained higher in the frank hypophosphatemia group, suggesting association between phosphorus and skeletal complications is not explained by differences in FD burden alone.
Conclusion
Both frank hypophosphatemia and low-normophosphatemia are associated with increased FD-related complications. This supports FGF23-mediated hypophosphatemia as a driver of skeletal morbidity, which may impact a larger proportion of the FD/McCune-Albright syndrome population than previously recognized. These findings enable clinicians to identify at-risk patients and will inform development of prospective studies to determine optimal therapeutic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892, USA.
- Pediatric Endocrinology Inter-Institute Training Program, National Institute of Child Health and Development, National Institutes of Health, Bethesda, MD 20892, USA.
- Biostatistics and Clinical Epidemiology Service, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
ORCID-Profile: Alison M Boyce
Förderung
- CLC NIH HHS
- Intramural Research Programs
- NIH
- NIDCR
- NICHD
- Clinical Center
Zitieren
APA
Gun, Z. H., Osamor, C., Taylor, J., Li, X., Szymczuk, V., & Boyce, A. M. (2024). Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad671
Vancouver
Gun ZH, Osamor C, Taylor J, Li X, Szymczuk V, Boyce AM. Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad671
BibTeX
@article{Gun2024,
author = {Gun, Zubeyir Hasan and Osamor, Charles and Taylor, Jocelyn and Li, Xiaobai and Szymczuk, Vivian and Boyce, Alison M},
title = {Serum Phosphorus as a Driver of Skeletal Morbidity in Fibrous Dysplasia},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad671}
}
EUVIMED